Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Reboxetine (Edronax)].

D Souery1, J Sternon

  • 1Service de Psychiatrie, Hôpital Erasme, U.L.B.

Revue Medicale De Bruxelles
|February 15, 2000
PubMed
Summary
This summary is machine-generated.

Reboxetine, a novel antidepressant, selectively inhibits noradrenaline reuptake, showing efficacy comparable to SSRIs and tricyclics. Preliminary studies suggest a faster onset of action and improved social adjustment in patients with depression.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical factors predicting treatment resistant depression: affirmative results from the European multicenter study.

Acta psychiatrica Scandinavica·2018
Same author

Clinical correlates of augmentation/combination treatment strategies in major depressive disorder.

Acta psychiatrica Scandinavica·2018
Same author

New insights into the pharmacogenomics of antidepressant response from the GENDEP and STAR*D studies: rare variant analysis and high-density imputation.

The pharmacogenomics journal·2017
Same author

Traitement Des Infections Bronchopulmonaires Aigues Par Le Laurylsulfate De Tetracycline Intra-Musculaire.

Acta clinica Belgica·2016
Same author

Genetics of bipolar disorders.

Acta neuropsychiatrica·2016
Same author

Molecular genetic findings in mood disorders.

Acta neuropsychiatrica·2016
Same journal

[Breast cancer screening : a tool for informed decision making].

Revue medicale de Bruxelles·2018
Same journal

[Breast cancer screening : present situation and prospects].

Revue medicale de Bruxelles·2018
Same journal

[Guidelines in medical imaging : objectives, limits and radiation protection].

Revue medicale de Bruxelles·2018
Same journal

[How to avoid overmedicalization of the elderly patient ?]

Revue medicale de Bruxelles·2018
Same journal

[Ethical, pedagogical, socio-political and anthropological implications of quaternary prevention].

Revue medicale de Bruxelles·2018
Same journal

[New strategies in specific care for benign prostatic hypertrophy in older men].

Revue medicale de Bruxelles·2018
See all related articles

Area of Science:

  • Pharmacology
  • Neuroscience
  • Psychiatry

Background:

  • Depression is a prevalent mood disorder impacting millions globally.
  • Existing antidepressants include Selective Serotonin Reuptake Inhibitors (SSRIs) and tricyclic antidepressants.
  • There is a continuous need for antidepressants with improved efficacy and safety profiles.

Purpose of the Study:

  • To introduce reboxetine as a novel antidepressant agent.
  • To evaluate the efficacy and safety profile of reboxetine.
  • To compare reboxetine's action with existing antidepressant classes.

Main Methods:

  • Selective inhibition of noradrenaline reuptake (NARI) mechanism.
  • Comparison of efficacy with tricyclic antidepressants and SSRIs.

Related Experiment Videos

  • Assessment of onset of action and social adjustment improvements.

    • Main Results:

    • Reboxetine demonstrates efficacy comparable to established antidepressants.
    • Preliminary data suggest a mean onset of action around 10 days.
    • Reboxetine appears to enhance social adjustment in depressed patients.
    • The drug exhibits a favorable safety profile due to its selectivity.

    Conclusions:

    • Reboxetine represents a promising new option for depression treatment.
    • Its selective noradrenaline reuptake inhibition offers a favorable safety profile.
    • Further research is needed to clarify its use in combination therapy.